VIDEO: Ellipsoid zone an important biomarker in geographic atrophy
Click Here to Manage Email Alerts
In this video, Barbara Blodi, MD, discusses the importance of the ellipsoid zone as a biomarker in patients with geographic atrophy.
“There are now AI systems that can measure the ellipsoid zone — its presence or absence or disruption,” Blodi said during a recap about presentations from the ASRS annual meeting.
The FDA recognizes change or loss of the ellipsoid zone (EZ) as an outcome in patients with geographic atrophy (GA), according to Blodi, professor in the department of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health.
“EZ is a really important biomarker,” she said. “We need to learn more about the EZ, and can it help us identify areas at risk and predict those future areas of GA.”
Reference:
- Talcott K, et al. Baseline ellipsoid zone integrity features as predictors of geographic atrophy growth rate in the phase 3 GATHER clinical trials. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts